| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,720 | 0,730 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.11. | LAEKNA-B Completes Phase I SAD Study of LAE103 in Overweight or Obese Subjects | 2 | AASTOCKS | ||
| 09.11. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF PHASE I SAD STUDY OF LAE103 IN OVERWEIGHT OR OBESE PARTICIPANTS | 1 | HKEx | ||
| 13.10. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT UPDATES ON THE 24-WEEK MONOTHERAPY STUDY OF LAE102 SHOWED PROMISING WEIGHT LOSSES FAVORABLE CHANGES IN BODY COMPOSITION ... | 1 | HKEx | ||
| 18.09. | LAEKNA-B (02105): INTERIM REPORT 2026 | 2 | HKEx | ||
| 08.09. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 01.09. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE I CLINICAL STUDY OF LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR) | 3 | HKEx | ||
| 25.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 17.08. | LAEKNA-B (02105): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 12.08. | Laekna's breast cancer drug application accepted in China | 1 | Investing.com | ||
| 12.08. | Laekna: New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration | 302 | PR Newswire | SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center... ► Artikel lesen | |
| 12.08. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR LAE002 (AFURESERTIB) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| 07.08. | LAEKNA-B (02105): DATE OF BOARD MEETING | 3 | HKEx | ||
| 09.07. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.07. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASES UNDER THE REPURCHASE MANDATE AND PROPOSED SHARE PURCHASE BY SENIOR MANAGEMENT | 3 | HKEx | ||
| 29.06. | LAEKNA-B (02105): UPDATE ON QUALIFICATION OF COMPANY SECRETARY; RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE | - | HKEx | ||
| 10.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH VASQUE BIO FOR LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR) IN ... | 2 | HKEx | ||
| 05.06. | LAEKNA-B (02105): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026 | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |